Article
Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib.
Molecular oncology - 1 Apr 2026
Balaseviciute Ugne, Huguet-Pradell Júlia, Abril-Fornaguera Jordi, Gris-Oliver Albert, Rialdi Alex, Fernández-Martínez Elisa, Montironi Carla, Del Pozo Vanessa, Houghton Peter, Zanatto Laura, Mesropian Agavni, Keraite Ieva, Thung Swan, Armengol Carolina, Sancho-Bru Pau, Guccione Ernesto, Pinyol Roser, Llovet Josep M
Abstract excerpt
Hepatoblastoma (HB), the most frequent pediatric liver cancer (2.16 cases/million), has surgery and perioperative chemotherapy as primary treatment, with severe lifelong side effects. This study evaluates the efficacy of the Wnt/CTNNB1 inhibitor WNTinib as a potential HB treatment, since CTNNB1 mutations occur in 70-90% of HBs. WNTinib's efficacy was assessed in three animal models (n = 48): (a) patient-derived...
Topics
Join the communities discussing this publication.